BAX — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL609012	1.00	2/20
SCHEMBL609455	1.00	2/20
SCHEMBL610221	1.00	2/20
SCHEMBL607333	0.88	2/20
SCHEMBL607334	0.88	2/20
SCHEMBL608294	0.88	2/20
SCHEMBL607098	0.72	2/20
SCHEMBL607341	0.72	2/20
SCHEMBL607745	0.72	2/20
SCHEMBL607771	0.72	2/20
SCHEMBL410834	0.70	2/20
SCHEMBL607396	0.69	2/20
SCHEMBL608466	0.67	2/20
SCHEMBL609179	0.67	2/20
SCHEMBL609293	0.67	2/20
SCHEMBL609683	0.67	2/20
SCHEMBL606837	0.66	2/20
SCHEMBL607023	0.66	2/20
SCHEMBL607965	0.66	2/20
SCHEMBL609128	0.65	2/20

Clinical trials — most relevant to BAX by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)	PHASE2/PHASE3	COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	PHASE2	COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL	PHASE2	RECRUITING
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer	PHASE2	COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors	PHASE1	UNKNOWN
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	PHASE1	COMPLETED
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases	PHASE1	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Smoking Influence on Apoptosis in Periodontitis	nan	COMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer	nan	COMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia	nan	COMPLETED
The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT	nan	UNKNOWN
Impact of CASP3 Gene in Chemoresistance	nan	NOT_YET_RECRUITING
Gene Expression Profiles in Patients With Permanent Atrial Fibrillation (AF) Versus Sinus Rhythm (SR)	nan	UNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure	nan	RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis	nan	COMPLETED
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML	nan	RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BAX binder may also engage these)

Protein	Name	Similarity
O02703	—	1.000	O02703 →
Q07813	—	1.000	Q07813 →
Q63690	—	1.000	Q63690 →
Q91828	—	0.994	Q91828 →
Q07816	—	0.993	Q07816 →
O08734	—	0.992	O08734 →
P53563	—	0.986	P53563 →
BCL2L1	Bcl-2-like protein 1	0.986	landscape →
Q64373	—	0.985	Q64373 →
A1L2I9	—	0.985	A1L2I9 →
BAK1	Bcl-2 homologous antagonist/killer	0.985	landscape →
O77737	—	0.985	O77737 →
Q1RMX3	—	0.984	Q1RMX3 →
Q9Z0F3	—	0.984	Q9Z0F3 →
Q0II48	—	0.984	Q0II48 →
Q28FG4	—	0.983	Q28FG4 →
Q6DC66	—	0.983	Q6DC66 →
Q08ED0	—	0.983	Q08ED0 →
Q6GMB1	—	0.983	Q6GMB1 →
Q9UKV5	—	0.983	Q9UKV5 →
Q9JLT6	—	0.982	Q9JLT6 →
Q99M66	—	0.982	Q99M66 →
Q91827	—	0.982	Q91827 →
P70345	—	0.982	P70345 →
A1L3G9	—	0.981	A1L3G9 →
Q45T69	—	0.981	Q45T69 →
BCL2A1	Bcl-2-related protein A1	0.981	landscape →
BCL2L2	Bcl-2-like protein 2	0.981	landscape →
Q5HZP8	—	0.980	Q5HZP8 →
Q7T381	—	0.980	Q7T381 →